Common colds incur significant costs in terms of sick leave and personal discomfort
for affected individuals. This study investigated the performance of
ColdZyme？ Mouth Spray (ColdZyme), a protective barrier against common
cold, in rhinovirus-inoculated healthy volunteers. This randomized, doubleblind,
placebo-controlled pilot study was conducted on 46 healthy volunteers
inoculated with rhinovirus 16 via the nose. Subjects self-administered ColdZyme or placebo 6 times daily for 11 days. Symptoms were recorded daily in a
diary. Rhinovirus 16 in nasal and oropharyngeal samples at days 0, 3, 4, 6, 7
and 10 were quantified by RT-qPCR. The primary outcome measure was the
reduction in viral load in oropharyngeal samples. Rhinovirus 16 was only detected
in 35 out of 46 inoculated subjects. Exploratory analysis measuring the
total viral load (i.e., area under the curve (AUC)) for days 3 - 10 in successfully
inoculated subjects found that ColdZyme treatment resulted in a lower total
viral load in the oropharynx (p = 0.023). In subjects who experienced symptomatic
common cold, irrespectively, if virus were detected, treatment with
ColdZyme resulted in a reduction in the number of days with common cold
symptoms from 6.5 to 3.0 days (p = 0.014) in comparison to placebo. ColdZyme reduced virus infection in the oropharynx and reduced the number of
days with common cold symptoms and highlights the possible importance of
the oropharynx in common cold infections. Suitable outcome measures for a
feasible study on ColdZyme are total viral load in the oropharynx in subjects
having detectable virus present in nasal or oropharyngeal samples.
References
[1]
Johnston, S.L., Pattemore, P.K., Sanderson, G., Smith, S., Lampe, F., Josephs, L., Symington, P., O’Toole, S., Myint, S.H., Tyrrell, D.A.J. and Holgate, S.T. (1995) Community Study of Role of Viral Infections in Exacerbations of Asthma in 9-11 Year Old Children. BMJ, 310, 1225-1229.
https://doi.org/10.1136/bmj.310.6989.1225
[2]
Bramley, T.J., Lerner, D. and Sarnes, M. (2002) Productivity Losses Related to the Common Cold. Journal of Occupational and Environmental Medicine, 44, 822-829.
https://doi.org/10.1097/00043764-200209000-00004
[3]
Arruda, E., Pitkaranta, A., Witek, T.J., Doyle, C.A. and Hayden, F.G. (1997) Frequency and Natural History of Rhinovirus Infections in Adults during Autumn. Journal of Clinical Microbiology, 35, 2864-2868.
[4]
Heikkinen, T. and Järvinen, A. (2003) The Common Cold. The Lancet, 361, 51-59.
https://doi.org/10.1016/S0140-6736(03)12162-9
[5]
Vareille, M., Kieninger, E. and Edwards, M.R. (2011) The Airway Epithelium: Soldier in the Fight against Respiratory Viruses. Clinical Microbiology Reviews, 24, 210-229. https://doi.org/10.1128/CMR.00014-10
[6]
Hayden, F.G., Turner, R.B., Gwaltney, J.M., Chi-Burris, K., Gersten, M., Hsyu, P., Patick, A.K., Smith, G.J. and Zalman, L.S. (2003) Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 47, 3907-3916.
https://doi.org/10.1128/AAC.47.12.3907-3916.2003
[7]
Bardin, P.G., Sanderson, G., Robinson, B.S., Holgate, S.T. and Tyrrell, D.A. (1996) Experimental Rhinovirus Infection in Volunteers. The European Respiratory Journal, 9, 2250-2255. https://doi.org/10.1183/09031936.96.09112250
[8]
Jackson, G.G., Dowling, H.F., Spiesman, I.G. and Boand A.V. (1958) Transmission of the Common Cold to Volunteers under Controlled Conditions. I. The Common Cold as a Clinical Entity. A.M.A. Archives of Internal Medicine, 101, 267-278.
https://doi.org/10.1001/archinte.1958.00260140099015
[9]
Greiff, L., Andersson, M. and Persson, C.G.A. (2001) Nasal Secretions and Exudations: Collection and Approaches to Analysis. In: Rogers, D.F. and Donnelly, L.E., Eds., Methods in Molecular Medicine, Humana Press, Totowa, 56, 61-73.
[10]
Gwaltney, J.M., Hendley, J.O. and Patrie, J.T. (2003) Symptom Severity Patterns in Experimental Common Colds and Their Usefulness in Timing Onset of Illness in Natural Colds. Clinical Infectious Diseases, 36, 714-723.
https://doi.org/10.1086/367844
[11]
Jones, R.M. and Su, Y.M. (2015) Dose-Response Models for Selected Respiratory Infectious Agents: Bordetella pertussis, Group a Streptococcus rhinovirus and Respiratory Syncytial Virus. BMC Infectious Diseases, 15, 90.
https://doi.org/10.1186/s12879-015-0832-0
[12]
Kennedy, J.L., Turner, R.B., Braciale, T., Heymann, P.W. and Borish, L. (2012) Pathogenesis of Rhinovirus Infection. Current Opinion in Virology, 2, 287-293.
https://doi.org/10.1016/j.coviro.2012.03.008
[13]
Dhariwal, J., Edwards, M.R. and Johnston, S.L. (2013) Anti-Viral Agents: Potential Utility in Exacerbations of Asthma. Current Opinion in Pharmacology, 13, 331-336.
https://doi.org/10.1016/j.coph.2013.04.010
[14]
Dimopoulos, G., Lerikou, M., Tsiodras, S., Chranioti, A., Perros, E., Anagnostopoulou, U., Armaganidis, A. and Karakitsos P. (2012) Viral Epidemiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Pulmonary Pharmacology & Therapeutics, 25, 12-18. https://doi.org/10.1016/j.pupt.2011.08.004
[15]
Pavia, A.T. (2011) Viral Infections of the Lower Respiratory Tract: Old Viruses, New Viruses, and the Role of Diagnosis. Clinical Infectious Diseases, 52, 284-289.
https://doi.org/10.1093/cid/cir043
[16]
Papadopoulos, N.G., Bates, P.J., Bardin, P.G., Papi, A., Leir, S.H., Fraenkel, D.J., Meyer, J., Lackie, P.M., Sanderson, G., Holgate, S.T. and Johnston, S.L. (2000) Rhinoviruses Infect the Lower Airways. The Journal of Infectious Diseases, 181, 1875-1884. https://doi.org/10.1086/315513
